stockrowDianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
Follow DNTH
Alert me
Dianthus Therapeutics, Inc. (DNTH) Book value per share
Dianthus Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 12.8×, up 20.8% from 10.6× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 21.6×. Over the past ten years it has ranged from −954× (fiscal 2016) to 127× (fiscal 2018); the current reading is higher than 40% of that period. Dianthus Therapeutics, Inc. ranks 32nd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 12.8× | 20.76% |
| FY2024 | 10.6× | (67.71%) |
| FY2023 | 32.8× | (61.11%) |
| FY2022 | 84.3× | 67.61% |
| FY2021 | 50.3× | (4.09%) |
| FY2020 | 52.4× | (14.10%) |
| FY2019 | 61.0× | (51.84%) |
| FY2018 | 127× | — |
| FY2017 | −363× | — |
| FY2016 | −954× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 21.6× | 3.50% |
| Jun 2026 | 20.9× | (16.36%) |
| Mar 2026 | 25.0× | 95.75% |
| Dec 2025 | 12.8× | (11.63%) |
| 34 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| DNTH Dianthus Therapeutics, Inc. | 21.6× |
| MANE Veradermics Incorporated compare | 20.1× |
| CRSP CRISPR Therapeutics AG compare | 17.0× |
| EWTX Edgewise Therapeutics, Inc. compare | 15.0× |
| DFTX Definium Therapeutics, Inc. compare | 8.3× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 6.6× |
| COGT Cogent Biosciences, Inc. compare | 3.1× |
| ERAS Erasca, Inc. compare | 1.2× |
| TVTX Travere Therapeutics, Inc. compare | 0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on DNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement